Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)

To evaluate the addition of ofranergene obadenovec (ofra-vec, VB-111), a novel gene-based anticancer targeted therapy, to once a week paclitaxel in patients with recurrent platinum-resistant ovarian cancer (PROC). This placebo-controlled, double-blind, phase III trial (ClinicalTrials.gov identifier:...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical oncology 2024-01, Vol.42 (2), p.170-179
Hauptverfasser:	Arend, Rebecca C, Monk, Bradley J, Shapira-Frommer, Ronnie, Haggerty, Ashley F, Alvarez, Edwin A, Amit, Amnon, Alvarez Secord, Angeles, Muller, Carolyn, Casado Herraez, Antonio, Herzog, Thomas J, Tewari, Krishnansu S, Cohen, Joshua G, Huang, Marilyn, Yachnin, Adelya, Holeman, Laura L, Ledermann, Jonathan A, Rachmilewitz Minei, Tamar, Buyse, Marc, Fain Shmueli, Shifra, Lavi, Michal, Harats, Dror, Penson, Richard T
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Inhibitors - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Ovarian Epithelial - drug therapy Female Humans Neoplasm Recurrence, Local - drug therapy Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Paclitaxel Progression-Free Survival
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!